Pain Management · Anesthesiology · Internal Medicine · June 2026
A comprehensive, medically reviewed reference on oxycodone (OxyContin, Roxicodone) — covering its pharmacology, FDA-approved use for pain management, immediate-release and extended-release formulations, critical safety information, overdose recognition, and legal access for patients in the United States.
| Generic Name | Oxycodone hydrochloride |
| Brand Names | OxyContin (extended-release) · Roxicodone (immediate-release) · combination products including Percocet (with acetaminophen) |
| Drug Class | Semi-synthetic opioid agonist |
| FDA Approval | 1950 (oxycodone); 1995 (OxyContin extended-release formulation) |
| DEA Schedule | Schedule II controlled substance |
| Available Forms | Immediate-release tablets/capsules (5, 10, 15, 20, 30 mg) · extended-release tablets (10–80 mg) · oral solution |
| Onset of Action | Immediate-release: 10–15 minutes. Extended-release: gradual, sustained over 12 hours. |
| Duration of Effect | Immediate-release: 4–6 hours. Extended-release: approximately 12 hours per dose. |
| Half-Life | ~3–4.5 hours (immediate-release) |
| Boxed Warnings | Addiction, abuse, and misuse · life-threatening respiratory depression · neonatal opioid withdrawal syndrome · risks from concurrent benzodiazepine or CNS depressant use |
| Generic Available | Yes — generic oxycodone is widely available |
Oxycodone is a semi-synthetic opioid agonist derived from thebaine, an alkaloid found in the opium poppy. It has been used clinically since the early 20th century and remains one of the most prescribed opioid analgesics in the United States for the management of pain severe enough to require an opioid, when alternative treatments are inadequate. Oxycodone is available as a single-ingredient immediate-release product, a single-ingredient extended-release product (OxyContin), and in combination products with non-opioid analgesics such as acetaminophen.
Oxycodone is classified as a Schedule II controlled substance under U.S. federal law, reflecting both its accepted medical use and its high potential for abuse, physical dependence, and diversion. This classification carries specific prescribing restrictions, including a prohibition on telephone-authorized refills and stricter limits on prescription duration in many states, reflecting the seriousness with which oxycodone and other Schedule II opioids are regulated.
Opioid analgesics, including oxycodone, occupy a genuinely important place in the management of acute severe pain, cancer-related pain, and certain chronic pain conditions where other approaches have not provided adequate relief. At the same time, oxycodone carries substantial risks of addiction, overdose, and death, and its use requires careful patient selection, informed consent, and ongoing monitoring by a prescribing physician throughout treatment.
Oxycodone binds primarily to mu-opioid receptors in the central nervous system and, to a lesser extent, kappa-opioid receptors. Activation of mu-opioid receptors in the brain and spinal cord inhibits the transmission of pain signals, alters the emotional perception of pain, and produces the characteristic analgesic effect of opioid medications. The same receptor activity that relieves pain is also responsible for oxycodone's euphoric effects, its potential for misuse, and its depressant effects on the respiratory centers of the brainstem, which is the mechanism underlying opioid-related respiratory depression and overdose death.
Following oral administration, immediate-release oxycodone is absorbed relatively quickly, with peak plasma concentrations reached within approximately 1 hour and a relatively short elimination half-life of about 3 to 4.5 hours, corresponding to a duration of pain relief of roughly 4 to 6 hours. The extended-release formulation, OxyContin, uses a controlled-release technology designed to release the medication gradually over approximately 12 hours, intended to provide more consistent pain control across a full day with fewer peaks and troughs, and is intended only for patients who require continuous, around-the-clock opioid treatment for an extended period.
Immediate-release oxycodone is indicated for the management of pain severe enough to require an opioid and for which alternative treatments are inadequate, typically for acute pain or as needed dosing for breakthrough pain in patients also using a long-acting opioid.
OxyContin is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatments are inadequate. It is not indicated for as-needed pain relief and is specifically intended for patients who are already opioid-tolerant, meaning they have been taking a regular daily dose of an opioid for a period of time, given the significant overdose risk this formulation carries in opioid-naive patients. Extended-release tablets must be swallowed whole and never crushed, chewed, dissolved, or otherwise manipulated, as doing so can cause the entire 12-hour dose to be released and absorbed rapidly, which can be fatal.
| Feature | Oxycodone | Hydrocodone | Morphine | Hydromorphone (Dilaudid) |
|---|---|---|---|---|
| DEA Schedule | Schedule II | Schedule II | Schedule II | Schedule II |
| Relative Potency | Reference (1x, oral) | Roughly similar to slightly less potent | Less potent than oxycodone, oral | Considerably more potent than oxycodone |
| Onset (Immediate-Release) | 10–15 min | 10–20 min | 30–60 min | 15–30 min |
| Common Combination Products | With acetaminophen (Percocet) | With acetaminophen (Vicodin, Norco) | Rarely combined | Rarely combined |
| Extended-Release Available | Yes (OxyContin) | Yes (Hysingla ER) | Yes (MS Contin) | Yes (Exalgo) |
All Schedule II opioid analgesics carry a fundamentally similar risk profile centered on addiction, respiratory depression, and overdose, and the choice between them is made by the prescribing physician based on the specific pain condition, patient history, prior opioid exposure, and organ function, since some agents are cleared differently in patients with kidney or liver impairment. No opioid in this class should be considered inherently "safer" in a way that changes the fundamental precautions required for its use.
Oxycodone, in both its immediate-release and extended-release forms, is FDA-approved for the management of pain severe enough to require opioid treatment and for which alternative treatment options are inadequate. It is used across a range of clinical settings including post-surgical pain, cancer-related pain, and certain severe chronic pain conditions, always as part of an individualized treatment plan that considers non-opioid and non-pharmacological approaches first or alongside opioid therapy where appropriate. Current clinical guidelines emphasize using the lowest effective dose for the shortest duration consistent with treatment goals, particularly for acute, non-cancer pain.
Oxycodone dosing is individualized based on the severity of pain, prior opioid exposure, age, and organ function, and is determined and adjusted exclusively by the prescribing physician. The information below reflects standard FDA labeling and is provided for general educational reference; it is not a substitute for an individualized prescription.
| Immediate-Release, Opioid-Naive Adults | Typically initiated at the lowest effective dose (often 5–10 mg) every 4 to 6 hours as needed for pain, with dose and interval adjusted by the prescriber based on response. |
| Extended-Release, Opioid-Tolerant Patients Only | Dosed every 12 hours; the starting dose and any titration are determined entirely by the prescribing physician based on prior opioid exposure. Never initiated in opioid-naive patients due to substantial overdose risk. |
| Elderly or Debilitated Patients | Generally started at a lower dose with careful titration, given increased sensitivity to opioid effects and slower clearance. |
| Hepatic or Renal Impairment | Requires a lower starting dose and slower titration given reduced drug clearance and increased risk of accumulation. |
| Discontinuation After Extended Use | Should be tapered gradually under physician guidance to avoid opioid withdrawal symptoms; never stopped abruptly after regular use without medical supervision of the taper. |
Oxycodone dosing must be determined and changed only by the prescribing physician. Taking more than prescribed, taking doses more frequently than directed, or combining oxycodone with any other opioid, sedative, or alcohol without explicit medical guidance significantly increases the risk of life-threatening respiratory depression and death. If your current dose is not adequately controlling your pain, contact your prescriber rather than increasing the dose independently.
Immediate-release oxycodone is taken exactly as directed, generally every 4 to 6 hours as needed for pain, with or without food. Extended-release tablets must be swallowed whole, one at a time, with enough water to ensure complete swallowing, and taken at consistent 12-hour intervals as directed. Extended-release tablets must never be crushed, chewed, broken, or dissolved, as this destroys the controlled-release mechanism and can cause rapid absorption of the full dose, which has resulted in fatal overdoses.
Oxycodone should be taken only as prescribed, only by the person for whom it was prescribed, and only for the condition it was prescribed to treat. Any change in the level of pain, whether improved or worsened, should be reported to the prescribing physician rather than managed by independently adjusting the dose or frequency.
Oxycodone's side effect profile reflects its action throughout the central nervous system and gastrointestinal tract, consistent with opioid medications generally.
Constipation is extremely common and, unlike many other opioid side effects, typically does not improve over time with continued use; proactive management with adequate fluid intake, fiber, and, when directed by a physician, stool softeners or laxatives is standard practice for patients on ongoing opioid therapy. Nausea and drowsiness are also frequently reported, particularly when starting treatment or after a dose increase, and often improve somewhat with continued use. Dizziness, dry mouth, and sweating are also commonly reported.
Itching is a recognized opioid-related effect that does not necessarily indicate a true allergy. Mental clouding, difficulty concentrating, and mood changes may also occur, particularly at higher doses, and should be discussed with the prescribing physician if they interfere with daily functioning.
Oxycodone exposes patients to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Even when taken as prescribed, physical dependence can develop with regular use, and this risk should be assessed and discussed with the prescribing physician before starting treatment and monitored throughout its course.
Oxycodone can cause serious, life-threatening, or fatal respiratory depression, meaning dangerously slowed or shallow breathing. This risk is greatest during treatment initiation, after a dose increase, and when oxycodone is combined with other central nervous system depressants including benzodiazepines, alcohol, or other sedatives. Patients and household members should know the signs of respiratory depression and understand when to seek emergency help, detailed in the overdose section below.
Prolonged use of oxycodone during pregnancy can result in neonatal opioid withdrawal syndrome, a potentially life-threatening condition in the newborn that requires specialized medical management. Pregnant patients being treated with oxycodone should be under the care of a physician experienced in managing this risk.
Combining oxycodone with benzodiazepines or other medications that depress the central nervous system, including alcohol, can result in profound sedation, respiratory depression, coma, and death. This combination should be avoided unless a physician has specifically determined it is necessary and there is no safer alternative, in which case the lowest effective doses and shortest duration should be used with close monitoring.
Long-term opioid use, including oxycodone, has been associated with adrenal insufficiency, a condition in which the adrenal glands do not produce adequate levels of certain hormones. Symptoms include nausea, vomiting, fatigue, weakness, and low blood pressure, and should be evaluated by a physician if they develop during extended treatment.
Opioid-induced constipation can become severe enough to cause bowel obstruction in some patients, particularly with prolonged use. Proactive bowel regimen management, as directed by the prescribing physician, is an important part of long-term opioid therapy.
Signs of an oxycodone overdose include: extreme drowsiness or inability to wake the person, slow, shallow, or stopped breathing, pinpoint pupils, blue or gray lips or fingertips, limp body, and gurgling or choking sounds. This is a medical emergency. Call 911 immediately. If naloxone (Narcan) is available, administer it according to its instructions — naloxone can reverse an opioid overdose and is safe to give even if you are not certain opioids are involved. Continue to monitor the person and be prepared to administer additional doses of naloxone if breathing does not improve, as naloxone's effect can wear off before the opioid has fully cleared the body, and repeated dosing or ongoing emergency care may be needed. Stay with the person until emergency responders arrive.
Naloxone is widely available in the United States without a prescription at most pharmacies and is recommended for patients prescribed oxycodone, particularly those on higher doses, those with a history of substance use disorder, or those with household members including children who could be at risk of accidental exposure. Discuss obtaining naloxone with your pharmacist or physician as a standard safety precaution, not an indication of distrust or expected misuse — it is comparable to keeping a fire extinguisher in the home.
| Interaction | Mechanism | Clinical Consequence | Management |
|---|---|---|---|
| Benzodiazepines | Additive CNS and respiratory depression | Profound sedation, respiratory depression, coma, death — subject of an FDA boxed warning | Avoid combination unless deemed necessary by a physician with no safer alternative; use lowest effective doses with close monitoring. |
| Alcohol | Additive CNS and respiratory depression | Significantly increased overdose risk; extended-release formulations carry particular risk of rapid dose release ("dose dumping") with alcohol | Avoid alcohol entirely while taking oxycodone. |
| Other opioids | Additive opioid effect | Increased sedation and respiratory depression risk | Do not combine opioid medications unless specifically directed by the prescriber. |
| MAOIs | Potential for severe, unpredictable interaction | Risk of serotonin syndrome-like reaction or exaggerated opioid effect | Avoid use within 14 days of an MAOI unless under close physician supervision. |
| Strong CYP3A4 inhibitors or inducers | Altered oxycodone metabolism | Increased or decreased oxycodone plasma levels | Dose adjustment may be required; disclose all medications to the prescriber. |
| Muscle relaxants and sleep medications | Additive CNS depression | Increased sedation and respiratory depression risk | Disclose all medications; combination requires physician oversight. |
Significant respiratory depression: Contraindicated in patients with significant respiratory depression, particularly in an unmonitored setting without resuscitation equipment.
Acute or severe bronchial asthma: Contraindicated in unmonitored settings or without resuscitation equipment available.
Known or suspected gastrointestinal obstruction, including paralytic ileus: Contraindicated given the risk of worsening bowel obstruction.
Known hypersensitivity: Contraindicated in patients with a prior hypersensitivity reaction to oxycodone.
Concurrent or recent MAOI use: Requires caution and specialist guidance given the risk of a serious interaction.
History of substance use disorder: Requires careful risk-benefit assessment, enhanced monitoring, and often specialist involvement before initiating opioid therapy.
Pregnancy: Requires individualized risk-benefit discussion given the risk of neonatal opioid withdrawal syndrome with prolonged use; abrupt discontinuation during pregnancy is not recommended without medical guidance, given withdrawal risks to the fetus.
Take oxycodone exactly as prescribed — the correct dose, at the correct interval, for the condition it was prescribed to treat. Never adjust the dose, frequency, or formulation on your own.
Never crush, chew, break, or dissolve extended-release tablets. Doing so can release the full 12-hour dose at once and has caused fatal overdoses. Always swallow extended-release tablets whole.
Never combine oxycodone with alcohol, benzodiazepines, or other sedatives unless a physician has explicitly reviewed this combination and determined it is necessary, given the serious, potentially fatal respiratory depression risk this combination carries.
Consider keeping naloxone on hand, particularly if you are on a higher dose, have any risk factors for overdose, or live with others, including children, who could be exposed accidentally. Ask your pharmacist for guidance on obtaining and using it.
Store oxycodone securely, out of sight and reach of children, guests, and anyone else in the household, given both its overdose risk to children and its recognized potential for diversion.
Never share oxycodone with anyone else, regardless of their symptoms; doing so is illegal, and a dose safe for one person can be fatal for another, particularly someone who is opioid-naive.
Dispose of unused oxycodone promptly and properly through a DEA-authorized take-back program or pharmacy mail-back envelope; do not keep leftover opioid medication in the home longer than necessary.
Never stop oxycodone abruptly after regular use without medical guidance; a physician-supervised taper reduces the discomfort of opioid withdrawal and is the recommended approach to discontinuation.
In the United States, oxycodone is a Schedule II controlled substance available only through a valid prescription from a licensed prescriber, following clinical evaluation of the underlying condition causing pain. Schedule II status carries specific federal and state restrictions, including a prohibition on prescription refills without a new written or electronically transmitted prescription, and, in many states, limits on the initial quantity that can be prescribed for acute pain.
Prescribers generally review a patient's history using state prescription drug monitoring programs before initiating or continuing opioid therapy, and ongoing treatment typically involves regular follow-up visits, periodic reassessment of continued need, and, for longer-term use, a documented treatment agreement outlining expectations for safe use, storage, and monitoring.
Given oxycodone's Schedule II status, the serious risks associated with this medication, and the strict regulatory framework governing its prescribing and dispensing, it is not available through informal telehealth-only pathways in the way some lower-risk medications are; a genuine clinical evaluation and an in-person or fully compliant telehealth relationship with a prescriber, consistent with state and federal requirements for controlled substances, is required.
My Online Med Shop dispenses oxycodone strictly against a valid, verified prescription from a licensed prescriber, sourced exclusively from verified pharmaceutical manufacturers, with secure encrypted checkout, discreet packaging, and 24/7 customer support, in full compliance with federal and state controlled substance regulations.
OxyContin is the extended-release formulation of oxycodone, designed to release the medication gradually over approximately 12 hours for patients who need continuous, around-the-clock pain control and who are already opioid-tolerant. Immediate-release oxycodone, sold under names like Roxicodone or as a generic, releases its full dose promptly and is used for shorter-duration pain relief, typically every 4 to 6 hours as needed.
Physical dependence, in which the body adapts to the presence of the medication and experiences withdrawal symptoms if it is stopped abruptly, can develop with regular oxycodone use even when taken exactly as prescribed. This is distinct from addiction, which involves compulsive use despite harm, though both are recognized risks discussed in oxycodone's FDA boxed warning. Any plan to reduce or stop oxycodone after regular use should involve a physician-guided taper.
Contact your prescribing physician rather than taking an extra dose or taking it more frequently than prescribed. Inadequate pain control may call for a dose adjustment, a change in formulation, the addition of a non-opioid treatment, or further evaluation of the underlying cause of pain — all decisions that should be made by your physician based on a full clinical picture.
Opioids, including oxycodone, slow gastrointestinal motility by acting on opioid receptors in the gut, and unlike sedation or nausea, this effect typically does not improve with continued use. Because of this, a proactive bowel management plan — often including increased fluids, fiber, and, when directed by a physician, a stool softener or laxative — is standard for patients on ongoing oxycodone therapy rather than something to address only if it becomes a problem.
Many physicians and pharmacists now recommend that patients prescribed opioids, including oxycodone, keep naloxone on hand as a standard safety measure, particularly at higher doses or with any additional risk factors. Naloxone can reverse an opioid overdose and is safe to use; having it available does not indicate distrust of the patient and is comparable to other emergency preparedness measures like a fire extinguisher or first aid kit.
No. Alcohol significantly increases the risk of profound sedation and life-threatening respiratory depression when combined with oxycodone, and with extended-release formulations specifically, alcohol can also disrupt the controlled-release mechanism and cause the full dose to be released at once. Alcohol should be avoided entirely during oxycodone treatment.
Unused oxycodone should be disposed of promptly through a DEA-authorized drug take-back location or an at-home mail-back envelope, both of which are designed to safely and completely destroy leftover controlled substances. Keeping unused opioid medication in the home longer than necessary increases the risk of accidental exposure, misuse, or diversion.
Oxycodone remains an important tool in the management of severe pain, including post-surgical, cancer-related, and certain chronic pain conditions, when alternative treatments are inadequate. Its availability in both immediate-release and extended-release formulations allows treatment to be matched to the specific pattern and duration of pain a patient experiences.
As a Schedule II controlled substance carrying multiple FDA boxed warnings — for addiction, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, and the dangers of combining it with benzodiazepines or other CNS depressants — oxycodone requires exceptionally careful, physician-guided use, informed patient understanding of overdose risk, and, for many patients, the presence of naloxone in the home as a standard safety precaution.
Within the parameters of a valid prescription, honest communication with the prescribing physician, and strict adherence to the prescribed dose and formulation, oxycodone has a long-established record as an effective treatment for severe pain — one that demands ongoing respect for its serious risks at every stage of treatment.
Buy Oxycodone Online USA: Uses, Dosage & Safety Guide 2026
Buy Oxandrolone Online USA: Uses, Dosage & Safety Guide 2026
Buy Anadrol-50 Online USA: Uses, Dosage & Safety Guide 2026
Buy Escitalopram Online USA: Uses, Dosage & Safety Guide 2026